Business Context and Reporting Period
Company: BlackRock TCP Capital Corp. (TCPC)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2019
Business Model: Externally managed, closed-end, non-diversified Business Development Company (BDC) regulated under the Investment Company Act of 1940. The Company invests primarily in debt securities of middle-market companies (enterprise values $100M–$1.5B), focusing on senior secured loans. It also holds equity interests and warrants. Investment operations are conducted through wholly-owned subsidiaries (SVCP, TCPC Funding, and the SBIC). The investment advisor is Tennenbaum Capital Partners, LLC (an indirect subsidiary of BlackRock, Inc.).
Key Financial Metrics (Year Ended Dec 31, 2019)
| Metric | 2019 Value | 2018 Value |
|---|---|---|
| Total Investment Income | $195.2 million | $190.5 million |
| Net Investment Income | $94.9 million | $93.4 million |
| Net Realized and Unrealized Loss | ($64.3 million) | ($47.9 million) |
| Net Increase in Net Assets from Operations | $30.6 million | $45.5 million |
| Net Assets | $776.3 million | $830.5 million |
| Net Assets Per Share | $13.21 | $14.13 |
| Total Debt Outstanding (Principal) | $915.5 million | $805.2 million (carrying value) |
| Asset Coverage Ratio | 199% | 200% (approx.) |
| Weighted-Average Effective Yield (Debt Portfolio) | 10.3% | 11.4% |
| Dividends Declared Per Share | $1.44 | $1.44 |
Material Changes vs. Prior Period
- Net Assets Decline: Net assets decreased by approximately $54.2 million (6.5%) from 2018 to 2019, driven primarily by a net realized and unrealized loss of $64.3 million, partially offset by net investment income.
- Realized Losses: Net realized losses increased significantly to $76.6 million in 2019 compared to $28.8 million in 2018. Major contributors included a $56.6 million loss on the restructuring of the Fidelis investment and a $20.5 million loss on the disposition of the Green Biologics investment.
- Unrealized Gains: Unlike 2018, which saw a net unrealized depreciation of $19.1 million, 2019 recorded a net unrealized appreciation of $12.3 million, driven by gains on Edmentum ($13.4M) and 36th Street ($6.3M), and reversals of prior losses.
- Expense Structure: Total operating expenses rose to $100.3 million from $97.0 million. Interest expense increased due to higher debt levels, while incentive fees decreased to $20.3 million from $23.3 million following a reduction in the incentive fee rate from 20% to 17.5% effective February 9, 2019.
- Portfolio Composition: The portfolio grew to $1.65 billion (fair value) with 105 companies. Debt investments comprised 93.1% of the portfolio, with 86.6% in senior secured loans.
Guidance, Outlook, and Risks
- Management Commentary: Management noted that the decrease in net assets was primarily due to higher net realized and unrealized losses. The Company maintained its quarterly dividend of $0.36 per share ($1.44 annualized).
- Recent Developments (Post-Year-End):
- Invested approximately $65.9 million in three senior secured loans (Jan–Feb 2020).
- Fitch Ratings initiated an investment-grade rating of BBB- with a stable outlook on January 31, 2020.
- Board re-approved the $50 million stock repurchase plan on February 20, 2020.
- Declared a Q1 2020 dividend of $0.36 per share on February 26, 2020.
- Key Risks:
- Interest Rate Risk: 92.1% of the debt portfolio bears floating rates. Rising rates increase interest income but also increase borrowing costs.
- Liquidity and Leverage: The Company relies on a leverage program (SVCP Facility, TCPC Funding Facility, Notes, SBA Debentures). Failure to renew facilities or meet covenants could force asset sales.
- Valuation Uncertainty: 91.6% of investments are Level 3 (unobservable inputs), creating uncertainty regarding fair value versus realized proceeds.
- Concentration: Software is the largest industry concentration. The five largest investments comprised 17.2% of the portfolio.
Investor Verification Checklist
- Realized Loss Drivers: Verify the specific terms and recovery prospects of the Fidelis and Green Biologics restructurings/dispositions that drove the $76.6M realized loss.
- Asset Coverage Compliance: Confirm the Company remains in compliance with the 150% asset coverage requirement under the 1940 Act, especially given the decline in Net Asset Value.
- Debt Maturity Wall: Review the maturity schedule of the Leverage Program (SVCP and TCPC Funding Facilities mature in 2023; Notes in 2022 and 2024) and assess refinancing risks.
- Level 3 Valuations: Scrutinize the unobservable inputs (discount rates, multiples) used to value the 91.6% of the portfolio classified as Level 3 assets.
- Dividend Sustainability: Assess whether Net Investment Income ($94.9M) is sufficient to cover the annual dividend obligation ($84.6M) and interest expenses without eroding capital further.